WP5 JA1 Pilot Pazopanib Report+Appendix
The final version of the WP5 JA1 pilot assessment using the draft model for Rapid Relative Effectiveness Assessment of Pharmaceuticals and guidelines. The joint assessment involved the participation of 22 HTA organisations as authors on different domains or as reviewers. Find the full list on page 16 in side the report. The final version of the WP5 […]
Public consultation of the Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals
This document presents the public consultation of WP5 Joint Action Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals. The Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals under production by Work Package 5 Joint Action 1 were open for public consultation during the following periods: 29 June – 10 September 2012 […]
Methodological guideline for REA of pharmaceuticals: Composite endpoints
This guideline provides a set of recommendations for the selection and assessment of clinical endpoints when completing a Relative Effectiveness Assessment (REA) of pharmaceuticals. A composite endpoint (CE) consists of two or more single events combined in one outcome that should represent an overall clinically relevant and valid measure of clinical benefit due to treatment. […]
Methodological guideline for REA of pharmaceuticals: Internal validity
This guideline focuses on the assessment of the risk of bias of randomized controlled trials (RCTs), the most relevant trials for relative effectiveness assessment (REA) of pharmaceuticals. The quality assessment of non-randomized and diagnostic accuracy studies will be elaborated in separate guidelines. Likewise, a separate guideline deals with the problem of assessing applicability. Internal validity describes […]
Methodological guideline for REA of pharmaceuticals: Applicability of evidence in the context of a REA
This guideline provides a set of recommendations and aspects to be considered for the assessment of applicability in the context of a relative effectiveness assessment. Applicability, also known as external validity/ generalisability/ or transposability, is the extent to which the effects observed in clinical studies are likely to reflect the expected results when a specific […]
List of comments for the WP5 JA1 Pilot Pazopanib Report
The list of comments for the WP5 JA1 Pilot Pazopanib Report. The list provides the contact information of all the organisations that properly submitted their contributions. The list of comments for the WP5 JA1 Pilot Pazopanib Report. The list provides the contact information of all the organisations that properly submitted their contributions. This document is […]
List of commentators for the WP5 JA1 Pilot Pazopanib Report
The list with commentators provides the contact information of all the organisations that properly submitted contributions. The list with commentators provides the contact information of all the organisations that properly submitted contributions. List of commentators for the WP5 JA1 Pilot Pazopanib Report
JA1 Technical Report – WP1: Appendix 2
This document is Appendix 2 for WP1 under the JA1 Final Technical Report: “EUnetHTA Plenary Assembly meeting summary, May 24-25, 2012, Lisbon, Portugal” Please note that within this appendix, you will find references to its own set of 5 annexes. These are all included in the document attached below. NOTE: For the full Technical Report, […]
JA1 Technical Report – WP1: Appendix 1
This document is Appendix 1 for WP1 under the JA1 Final Technical Report: “WP1/Exec Comm f-t-f meeting summary, April 18-19, 2012, Rome, Italy” Please note that within this appendix, you will find references to its own set of 9 annexes. These are all included in the document attached below. NOTE: For the full Technical Report, […]
JA1 Technical Report – WP1: Appendices 4-8
This document consists of Appendices 4-8 for WP1 under the JA1 Final Technical Report: 4. EUnetHTA-EMA f-t-f meeting summary, February 11, 2010, London, UK 5. EUnetHTA-EMA f-t-f meeting summary, June 3, 2010, London, UK 6. EUnetHTA-EMA f-t-f meeting summary, March 7, 2011, Diemen, Netherlands 7. EUnetHTA-EMA f-t-f meeting summary, February 22, 2012, Paris, France 8. […]
